Targeting Drp1 in Cerebral Ischemia–Reperfusion Injury: Mechanisms and Therapeutic Implications
CNS Neuroscience & Therapeutics · 2025
DOI: 10.1111/cns.70590 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Mengnan Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, China. Hauptthemen laut MEDLINE: Dynamins, Reperfusion Injury, Brain Ischemia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Sichuan Province, Sichuan Province Science and Technology Support Program, The Innovation and Entrepreneurship Training Program for College Students.
Abstract (Originalsprache)
Background
Cerebral ischemia‐reperfusion injury (CIRI) arises after blood flow restoration in stroke, where reperfusion paradoxically triggers mitochondrial dysfunction, apoptosis, inflammation, and oxidative stress. Dynamin‐related protein 1 (Drp1), a regulator of mitochondrial fission, amplifies these cascades by promoting apoptosis, inflammatory signaling, and calcium imbalance.
Methods
This review synthesizes recent studies on Drp1 in CIRI, focusing on its regulatory roles in mitochondrial dynamics and neuronal injury, and evaluating therapeutic strategies through pharmacological and genetic modulation.
Results
Evidence shows Drp1 inhibition mitigates CIRI in preclinical models by restoring mitochondrial homeostasis, reducing oxidative stress, and improving neuronal survival. Promising interventions include selective inhibitors and genetic approaches, though challenges remain regarding drug specificity, delivery efficiency, and long‐term safety.
Conclusion
Drp1 is central to CIRI pathology and represents a promising therapeutic target. Future work should prioritize advanced delivery systems and safer, more selective Drp1 modulators to enable clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, China.
- Southwest Medical University, Luzhou, Sichuan, China.
- Department of Neurology, Minzu Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.
- Luhuo County Niba Township Health Center, Luhuo, Sichuan, China.
- Department of Neurology, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, China.
ORCID-Profile: Mengnan Liu, Xue Bai, Li Chen
Förderung
- Natural Science Foundation of Sichuan Province
- Sichuan Province Science and Technology Support Program
- The Innovation and Entrepreneurship Training Program for College Students
- Southwest Medical University Special Program for Integrated Traditional Chinese and Western Medicine
- Sichuan Provincial Science and Technology Support Program
Zitieren
APA
Liu, M., Yin, Z., Li, B., Qiu, J., Zhang, D., Wang, R., Bai, X., & Chen, L. (2025). Targeting Drp1 in Cerebral Ischemia–Reperfusion Injury: Mechanisms and Therapeutic Implications. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70590
Vancouver
Liu M, Yin Z, Li B, Qiu J, Zhang D, Wang R, et al. Targeting Drp1 in Cerebral Ischemia–Reperfusion Injury: Mechanisms and Therapeutic Implications. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70590
BibTeX
@article{Liu2025,
author = {Liu, Mengnan and Yin, Zhixue and Li, Binru and Qiu, Ji and Zhang, Dechou and Wang, Raoqiong and Bai, Xue and Chen, Li},
title = {Targeting Drp1 in Cerebral Ischemia–Reperfusion Injury: Mechanisms and Therapeutic Implications},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
doi = {10.1111/cns.70590}
}
EUVIMED